Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Dermatology

Finding Your Footing After a Pemphigus Vulgaris Diagnosis

At a Glance

Pemphigus vulgaris (PV) is a rare autoimmune disease that causes painful blisters, often starting in the mouth. While a diagnosis can be overwhelming, modern targeted treatments like rituximab are highly effective and make complete remission an achievable goal for most patients.

Receiving a diagnosis of Pemphigus Vulgaris (PV) can be overwhelming, especially after what was likely a long and painful search for answers. It is important to know that while your symptoms are severe, you have finally found the name of your condition, and there are highly effective modern treatments available to help you achieve remission.

Validating Your Journey

If you spent months or even years visiting various doctors before receiving this diagnosis, you are not alone [1]. Pemphigus Vulgaris is a rare autoimmune condition, meaning the immune system mistakenly attacks the body’s own healthy tissues [2]. Because it only affects approximately 2.83 people per million globally each year, many primary care doctors and dentists may never have seen a case before [3].

For about 90% of patients, the disease begins in the mouth with painful, non-healing sores [4]. These are often mistaken for common canker sores, infections, or gum disease, which frequently leads to significant diagnostic delays [5][6]. Recognizing that your frustration and physical pain are a documented part of this disease can be the first step toward healing.

Understanding the Disease

In PV, your immune system produces “autoantibodies” that target desmogleins, which are the “glue” proteins that hold your skin and mucous membrane cells together [7]. When this glue is attacked, the cells pull apart—a process called acantholysis—leading to the characteristic blisters and erosions you may be experiencing [8][9].

Three Stabilizing Facts

  1. Remission is the Goal: While PV was historically difficult to manage, modern medicine has transformed it into a treatable chronic condition. Achieving complete remission (a state where you have no new or existing lesions) is now the standard goal of care [10].
  2. Rituximab has Changed the Outlook: The introduction of Rituximab (a targeted biologic therapy) has revolutionized PV treatment [11]. It is often used as a first-line therapy because it is highly effective at inducing long-term remission and allows many patients to reduce or eventually stop taking high-dose steroids [12][13].
  3. You Are Not Your Diagnosis: Although PV is a serious, life-altering condition, the shift toward modern protocols is designed to reduce the risks once associated with the disease. With early intervention and expert care, most patients can return to their normal daily lives [14][15].

Navigating Your Demographics

PV does not discriminate by gender and its incidence has remained relatively stable over the last 50 years [3]. While it can affect anyone, certain genetic markers (specifically on the HLA genes) can make some ethnic populations more susceptible [16][17]. Regardless of your background, the most critical factor in your recovery is the prompt initiation of specialized treatment to stop the progression of the disease [14].

Moving Forward

The transition from the “search for a name” to the “start of a treatment” is a major milestone. Your care team will likely include a dermatologist (often one specializing in “immunodermatology”) and potentially an oral medicine specialist [18][6]. Together, you will focus on calming your immune system and allowing your skin and mucosa to heal.

Next: Learn more about Recognizing the Signs: How Pemphigus Vulgaris Behaves.

Common questions in this guide

Why did it take so long to get diagnosed with pemphigus vulgaris?
Pemphigus vulgaris is a rare disease that affects less than three people per million globally. Because it often begins with mouth sores, it is frequently mistaken for common conditions like canker sores or gum disease by primary care doctors and dentists, leading to delays.
What causes the blisters and mouth sores in pemphigus vulgaris?
In pemphigus vulgaris, your immune system mistakenly produces autoantibodies that attack desmogleins, which are the proteins that glue your skin and mucous membrane cells together. When these cells pull apart, it leads to the painful blisters and sores you experience.
What is the main goal of treatment for pemphigus vulgaris?
The primary goal of modern treatment is to achieve complete remission, meaning you have no new or existing sores. With proper medical care and targeted therapies, pemphigus vulgaris can be managed effectively, allowing most patients to return to their normal daily lives.
How does rituximab help treat pemphigus vulgaris?
Rituximab is a targeted biologic therapy that has revolutionized the treatment of this condition. It is often used as a first-line treatment because it targets the immune response causing the disease, allowing many patients to achieve remission and reduce or stop the use of high-dose steroids.
Which specialists should be on my care team for pemphigus vulgaris?
Your core care team will typically be led by a dermatologist, ideally an immunodermatologist who specializes in autoimmune skin diseases. Because the disease heavily impacts the mouth, working closely with an oral medicine specialist or specialized dentist is also highly recommended.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with Pemphigus Vulgaris do you or your practice treat annually?
  2. 2.What is my current 'antibody titer' for desmoglein 1 and 3, and how will we use these numbers to track my progress?
  3. 3.Given my specific health history, am I a candidate for first-line Rituximab, or do you recommend starting with high-dose corticosteroids first?
  4. 4.What is your protocol for preventing infections while I am on immunosuppressants?
  5. 5.Do you work closely with an oral medicine specialist or dentist to manage my mouth lesions?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Unusual Presentation of Pemphigus Vulgaris as a Solitary Ulcerative Scalp Lesion: A Case Report.

    Nejjari S, Basri G, Chikhaoui I, et al.

    Cureus 2025; (17(6)):e87025 doi:10.7759/cureus.87025.

    PMID: 40600094
  2. 2

    Pemphigus Vulgaris: Clinical Aspects and Treatments.

    Geng RSQ, Sibbald RG

    Advances in skin & wound care 2025; (38(5)):232-238 doi:10.1097/ASW.0000000000000307.

    PMID: 40184525
  3. 3

    The Global Incidence Rate of Pemphigus Vulgaris: A Systematic Review and Meta-Analysis.

    Zhao L, Chen Y, Wang M

    Dermatology (Basel, Switzerland) 2023; (239(4)):514-522 doi:10.1159/000530121.

    PMID: 36944327
  4. 4

    Prevalence of oral mucosal lesions in patients with pemphigus vulgaris: A systematic review and meta-analysis.

    Batistella EÂ, Sabino da Silva R, Rivero ERC, Silva CAB

    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2021; (50(8)):750-757 doi:10.1111/jop.13167.

    PMID: 33713362
  5. 5

    Oral Lesions in Autoimmune Bullous Diseases: An Overview of Clinical Characteristics and Diagnostic Algorithm.

    Rashid H, Lamberts A, Diercks GFH, et al.

    American journal of clinical dermatology 2019; (20(6)):847-861 doi:10.1007/s40257-019-00461-7.

    PMID: 31313078
  6. 6

    Anal involvement in patient with pemphigus vulgaris: Case report.

    Núñez-Rocha RE, Andrade-Restrepo J, Gómez-Carrillo D, et al.

    International journal of surgery case reports 2024; (114()):109185 doi:10.1016/j.ijscr.2023.109185.

    PMID: 38150999
  7. 7

    Pemphigus.

    Schmidt E, Kasperkiewicz M, Joly P

    Lancet (London, England) 2019; (394(10201)):882-894 doi:10.1016/S0140-6736(19)31778-7.

    PMID: 31498102
  8. 8

    Distinguishing histopathologic features of acantholytic dermatoses and the pattern of acantholytic hypergranulosis.

    See SHC, Peternel S, Adams D, North JP

    Journal of cutaneous pathology 2019; (46(1)):6-15 doi:10.1111/cup.13356.

    PMID: 30203619
  9. 9

    Pemphigus vulgaris - approach and management.

    Popescu IA, Statescu L, Vata D, et al.

    Experimental and therapeutic medicine 2019; (18(6)):5056-5060 doi:10.3892/etm.2019.7964.

    PMID: 31819769
  10. 10

    Biologics in autoimmune bullous diseases: Current scenario.

    Bishnoi A, De D, Handa S, Mahajan R

    Indian journal of dermatology, venereology and leprology 2021; (87(5)):611-620.

    PMID: 34245525
  11. 11

    Pemphigus Vulgaris: Present and Future Therapeutic Strategies.

    Didona D, Paolino G, Di Zenzo G, et al.

    Dermatology practical & conceptual 2022; (12(1)):e2022037 doi:10.5826/dpc.1201a37.

    PMID: 35223181
  12. 12

    Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.

    Werth VP, Joly P, Mimouni D, et al.

    The New England journal of medicine 2021; (384(24)):2295-2305 doi:10.1056/NEJMoa2028564.

    PMID: 34097368
  13. 13

    Rituximab: A Magic Bullet for Pemphigus.

    Anandan V, Jameela WA, Sowmiya R, et al.

    Journal of clinical and diagnostic research : JCDR 2017; (11(4)):WC01-WC06 doi:10.7860/JCDR/2017/21868.9717.

    PMID: 28571245
  14. 14

    Radiotherapy-induced pemphigus vulgaris: a challenging case of extensive mucocutaneous ulcerations and literature review.

    Santos BC, Ferraz DLF, Eleuterio MH, et al.

    Oral surgery, oral medicine, oral pathology and oral radiology 2026; (141(4)):495-502 doi:10.1016/j.oooo.2025.11.004.

    PMID: 41444035
  15. 15

    Serum levels of soluble PD1 in pemphigus vulgaris: A useful marker for disease severity.

    Zeid OA, Rashed L, Khalifa S, et al.

    Journal of cosmetic dermatology 2021; (20(4)):1298-1302 doi:10.1111/jocd.13719.

    PMID: 32920962
  16. 16

    Incidence and death rate of pemphigus vulgaris and pemphigus foliaceus in Korea: A nationwide, population-based study (2006-2015).

    Lee YB, Lee JH, Lee SY, et al.

    The Journal of dermatology 2018; (45(12)):1396-1402 doi:10.1111/1346-8138.14667.

    PMID: 30320467
  17. 17

    HLA-DRB1 and DQB1 genetic susceptibility to pemphigus vulgaris and pemphigus foliaceus in Vietnamese patients.

    Vuong TBT, Do DM, Ong PT, Thanh Le TV

    Dermatology reports 2022; (14(2)):9286 doi:10.4081/dr.2021.9286.

    PMID: 35795841
  18. 18

    Oral Pemphigus Vulgaris: Case Report.

    Arpita R, Monica A, Venkatesh N, et al.

    Ethiopian journal of health sciences 2015; (25(4)):367-72.

    PMID: 26949302

This page provides general educational information about a Pemphigus Vulgaris diagnosis. Always consult your immunodermatologist or primary specialist for personalized treatment decisions and disease management.

Get notified when new evidence is published on Pemphigus vulgaris.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.